TY - JOUR
T1 - The Levels of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 during the First Week after a Traumatic Brain Injury
T2 - Correlations with Clinical and Imaging Findings
AU - Posti, Jussi P.
AU - Takala, Riikka S.K.
AU - Runtti, Hilkka
AU - Newcombe, Virginia F.
AU - Outtrim, Joanne
AU - Katila, Ari J.
AU - Frantzén, Janek
AU - Ala-Seppälä, Henna
AU - Coles, Jonathan P.
AU - Iftakher Hossain, M.
AU - Kyllönen, Anna
AU - Maanpää, Henna Riikka
AU - Tallus, Jussi
AU - Hutchinson, Peter J.
AU - Van Gils, Mark
AU - Menon, David K.
AU - Tenovuo, Olli
N1 - Publisher Copyright:
© 2016 by the Congress of Neurological Surgeons.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background: Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) are promising biomarkers of traumatic brain injury (TBI). OBJECTIVE: We investigated the relation of the GFAP and UCH-L1 levels to the severity of TBI during the first week after injury. METHODS: Plasma UCH-L1 and GFAP were measured from 324 consecutive patients with acute TBI and 81 control subject enrolled in a 2-center prospective study. The baseline measures included initial Glasgow Coma Scale (GCS), head computed tomographic (CT) scan at admission, and blood samples for protein biomarkers that were collected at admission and on days 1, 2, 3, and 7 after injury. RESULTS: Plasma levels of GFAP and UCH-L1 during the first 2 days after the injury strongly correlated with the initial severity of TBI as assessed with GCS. Additionally, levels of UCH-L1 on the seventh day after the injury were significantly related to the admission GCS scores. At admission, both biomarkers were capable of distinguishing mass lesions from diffuse injuries in CT, and the area under the curve of the receiver-operating characteristic curve for prediction of any pathological finding in CT was 0.739 (95% confidence interval, 0.636-0.815) and 0.621 (95% confidence interval, 0.517-0.713) for GFAP and UCH-L1, respectively. CONCLUSION: These results support the prior findings of the potential role of GFAP and UCH-L1 in acute-phase diagnostics of TBI. The novel finding is that levels of GFAP and UCH-L1 correlated with the initial severity of TBI during the first 2 days after the injury, thus enabling a window for TBI diagnostics with latency.
AB - Background: Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) are promising biomarkers of traumatic brain injury (TBI). OBJECTIVE: We investigated the relation of the GFAP and UCH-L1 levels to the severity of TBI during the first week after injury. METHODS: Plasma UCH-L1 and GFAP were measured from 324 consecutive patients with acute TBI and 81 control subject enrolled in a 2-center prospective study. The baseline measures included initial Glasgow Coma Scale (GCS), head computed tomographic (CT) scan at admission, and blood samples for protein biomarkers that were collected at admission and on days 1, 2, 3, and 7 after injury. RESULTS: Plasma levels of GFAP and UCH-L1 during the first 2 days after the injury strongly correlated with the initial severity of TBI as assessed with GCS. Additionally, levels of UCH-L1 on the seventh day after the injury were significantly related to the admission GCS scores. At admission, both biomarkers were capable of distinguishing mass lesions from diffuse injuries in CT, and the area under the curve of the receiver-operating characteristic curve for prediction of any pathological finding in CT was 0.739 (95% confidence interval, 0.636-0.815) and 0.621 (95% confidence interval, 0.517-0.713) for GFAP and UCH-L1, respectively. CONCLUSION: These results support the prior findings of the potential role of GFAP and UCH-L1 in acute-phase diagnostics of TBI. The novel finding is that levels of GFAP and UCH-L1 correlated with the initial severity of TBI during the first 2 days after the injury, thus enabling a window for TBI diagnostics with latency.
KW - Biomarker
KW - GFAP
KW - Severity
KW - Traumatic brain injury
KW - UCH-L1
UR - http://www.scopus.com/inward/record.url?scp=84960355868&partnerID=8YFLogxK
U2 - 10.1227/NEU.0000000000001226
DO - 10.1227/NEU.0000000000001226
M3 - Article
C2 - 26963330
AN - SCOPUS:84960355868
SN - 0148-396X
VL - 79
SP - 456
EP - 463
JO - Neurosurgery
JF - Neurosurgery
IS - 3
ER -